China-based RemeGen (HKG: 9995) has announced plans to raise RMB 2.55 billion (approximately USD 280.5 million) through a private placement. The funds will be directed towards supporting clinical studies and the development of innovative therapies, including candidates RC18, RC48, RC28, RC88, RC148, and RC198.
With a robust product portfolio featuring over 20 biologics, RemeGen has 10 products that are either already commercialized or in various clinical stages. Key offerings include the fusion protein drug telitacicept, the antibody-drug conjugate (ADC) disitamab vedotin (RC48), and RC28, a fusion protein targeting VEGF and FGF for ophthalmological applications.- Flcube.com
